Group 1 - The core focus of the company is on the research, development, production, and commercialization of inhalation technology and inhalation drugs for treating respiratory diseases [3] - The company has received six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) during the reporting period [3] - CF017, an inhalation suspension of budesonide for treating bronchial asthma, is the company's first approved product and has quickly become a leading inhalation drug in China [3][4] Group 2 - CF017 is projected to account for approximately 16% of the Chinese budesonide inhalation drug market by sales volume in 2024 [3] - The company's revenue is expected to grow significantly from RMB 349.1 million in 2022 to RMB 607.8 million in 2024, representing a compound annual growth rate (CAGR) of 31.9% [3] - The inhalation formulation market for respiratory diseases is expected to represent about 27.9% of the total respiratory drug market in China by 2024 [4] Group 3 - The company recorded a net loss of RMB 49.4 million in 2022, primarily due to the large-scale commercialization of CF017 starting in September 2021 [4] - The company achieved profitability in 2023, with net profit increasing from RMB 6.2 million in the first three months of 2024 to RMB 12.8 million in the same period of 2025 [4] - The increase in profit is attributed to the integration of third-party promotional functions into the company's distributors, streamlining sales and marketing practices [4]
长风药业（02652.HK）招股在即，吸入布地奈德市场份额达16%